ORIC Pharmaceuticals Q2 EPS $(0.45) Misses $(0.41) Estimate
Portfolio Pulse from Benzinga Newsdesk
ORIC Pharmaceuticals (NASDAQ:ORIC) reported a Q2 EPS of $(0.45), missing the analyst consensus estimate of $(0.41) by 9.76%. This represents a 10% improvement over the $(0.50) per share loss from the same period last year.
August 12, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ORIC Pharmaceuticals reported a Q2 EPS of $(0.45), missing the analyst consensus estimate of $(0.41) by 9.76%. Despite the miss, this is a 10% improvement over the $(0.50) per share loss from the same period last year.
The miss on EPS estimates is likely to have a negative short-term impact on ORIC's stock price. However, the 10% improvement over last year's loss may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100